The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

In the second study, Nallasivan Palanisamy and co-workers report that 1–2% of prostate cancers harbor gene fusions involving RAF kinase genes, rather than classical ETS family transcription factors.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

We have investigated the prediction of protein interactions through the analysis of domain fusion to assess whether metabolic enzymes have a higher participation in gene-fusion events compared ...

Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers. Gene rearrangements/fusions identified per year.

Genetic medicines could treat certain diseases, however, the current delivery systems available—viral vectors and lipid nanoparticles (LNPs)—pose unique challenges for gene therapy applications. For ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

Prognostic factors for thermo-ablation of liver metastases in colon cancer: A Maltese perspective. Impact of sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...